# Giammaria Giuliani

> Giammaria Giuliani is a Series B investor in Montagnola backing Beauty and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Location: Montagnola, Switzerland
- Total investments: 5
- Last investment: Sep 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/giammaria-giuliani-1a49b01/

Giammaria Giuliani is a Series B investor in Montagnola focused on Beauty and Biopharma. Giammaria Giuliani

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $22M–$43M |
| Series C | $28M–$39M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Beauty | 1 | 20% |
| Biopharma | 1 | 20% |
| Cosmetics | 1 | 20% |
| Health Care | 1 | 20% |
| Therapeutics | 1 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 40% |
| Series A | 1 | 20% |
| Series C | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 1 | 20% |
| United States | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cutiss | CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $38.8M | Series C | Sep 10, 2025 |  |
| Cutiss | CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $27.5M | Series C | May 17, 2024 |  |
| Bionaut Labs | Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index forefficacy and maintain safety.Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings. | $43.2M | Series B | Nov 28, 2022 |  |
| Cutiss | CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $19.6M | Series B | Jun 04, 2020 |  |
| Cutiss | CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $8.5M | Series A | Jun 26, 2018 |  |

5 of 5 investments shown.

## Co-investors
- [Khosla Ventures](https://shizune.co/investors/profile/khosla-ventures) — VC Fund, 2 deals together
- [Shiloh Advisors](https://shizune.co/investors/profile/shiloh-advisors) — VC Fund, 2 deals together
- [Upfront Ventures](https://shizune.co/investors/profile/upfront-ventures) — VC Fund, 2 deals together
- [Bold Capital Partners](https://shizune.co/investors/profile/bold-capital) — VC Fund, 1 deal together
- [Deep Insight](https://shizune.co/investors/profile/deep-insight-6269) — VC Fund, 1 deal together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Unilever Ventures](https://shizune.co/investors/profile/unilever-ventures) — VC Fund
- [Fab Co-Creation Studio Ventures](https://shizune.co/investors/profile/fab-co-creation-studio-ventures) — VC Fund
- [Flybridge](https://shizune.co/investors/profile/flybridge-capital) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Consumer Angel Investors in Switzerland](https://shizune.co/investors/consumer-angel-investors-switzerland)
- [Marketplace Angel Investors in Switzerland](https://shizune.co/investors/marketplace-angel-investors-switzerland)
- [Beauty Investors in Switzerland](https://shizune.co/investors/beauty-investors-switzerland)
- [Beauty Angel Investors in Switzerland](https://shizune.co/investors/beauty-angel-investors-switzerland)

## FAQ

### What does Giammaria Giuliani invest in?

Giammaria Giuliani invests primarily in Beauty, Biopharma and Cosmetics startups, most often at Series B and Series A stage. Most of the 5 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Giammaria Giuliani's check size?

Giammaria Giuliani typically joins rounds of $22M–$43M at Series B and $28M–$39M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Giammaria Giuliani participates in.

### When did Giammaria Giuliani last invest?

The most recent investment recorded for Giammaria Giuliani closed in Sep 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co